Immunotherapy in Oncology Market to Grow at a CAGR of 11.60% During 2026-2035, Aided by the Rising Prevalence of Cancer Across the 8 Major Markets

Immunotherapy in Oncology Market Overview

Immunotherapy refers to a type of biological therapy that helps the immune system fight against cancer. Immune checkpoint inhibitors are a common type of immunotherapy that works by blocking immune checkpoints and stimulating immune cells to respond strongly to cancer. The rising prevalence of cancer and heightened awareness of immunotherapy as a treatment option are driving the market demand. Further, the expanding pipeline of novel immunotherapy agents and substantial funding for cancer research are expected to bolster market growth. Moreover, rising healthcare expenditure, a shift towards combination therapies, and favorable regulatory environment are some of the factors impacting the immunotherapy in oncology market dynamics.

Key Findings

• According to the American Cancer Society, around 2,114,850 new cancer cases and 626,140 cancer deaths are projected in the United States in 2026, sustaining strong demand for effective treatments including immunotherapy.
• Global cancer statistics from the American Cancer Society and IARC show nearly 21 million new cases and 9.8 million deaths worldwide in 2024, with the burden projected to reach 34 million cases by 2050, a 67% increase driven by population ageing and growth.
• Five-year cancer survival reached a milestone of 70% for diagnoses in 2015 to 2021, with metastatic melanoma survival rising from 16% to 35%, reflecting the impact of immunotherapy and other advances in disease-modifying cancer treatment.

Immunotherapy in Oncology Market Demand Drivers

According to the American Cancer Society, 2,001,140 new cases of cancer and 611,720 cancer deaths are predicted to occur in the United States in 2024. Further, the International Agency for Research on Cancer (IARC) revealed that around 1 in 5 individuals develop cancer in their lifetime. The rising burden of cancer is propelling the demand for effective treatments like immunotherapies. Moreover, the robust regulatory support from health agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) is anticipated to expedite the market entry of novel immunotherapies, thereby contributing to the market growth.

Immunotherapy in Oncology Market Segmentation Analysis

The Type Segment is Anticipated to Experience Significant Market Growth

Based on type, the market segmentation includes monoclonal antibodies, cytokines and immunomodulators, checkpoint inhibitors, and others. The monoclonal antibody segment holds a high market value which can be attributed to its proven efficacy and established use in the treatment of various types of cancer. Multiple monoclonal antibodies are approved by the regulatory bodies for diverse indications, which also boosts their market demand. Rituximab (for non-Hodgkin lymphoma) and Trastuzumab (for HER2-positive breast cancer) are some common examples of monoclonal antibodies.

The market report also offers insights based on the indication, route of administration, end user, and region.

Immunotherapy in Oncology Market: Competitive Landscape

• In 2025, Bristol-Myers Squibb's Opdivo (nivolumab) gained European approval for perioperative use in resectable non-small cell lung cancer with PD-L1 expression of 1% or greater, combining neoadjuvant Opdivo plus chemotherapy with adjuvant Opdivo, reinforcing its Opdivo and Yervoy checkpoint-inhibitor franchise.
• AstraZeneca continues to expand its Imfinzi (durvalumab) franchise across perioperative and combination regimens in lung, bladder, and other cancers, positioning it among the leading checkpoint inhibitors alongside its broader oncology portfolio.
• Other players include F. Hoffmann-La Roche, Pfizer, Novartis, Eli Lilly, Takeda, Amgen Inc., and Bayer, competing across checkpoint inhibitors, monoclonal antibodies, antibody-drug conjugates, and cell therapies.

Immunotherapy in Oncology Market Analysis by Region

North America is Projected to Lead the Market Share

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States represents a significant market share owing to the presence of the major pharmaceutical and biotechnology companies focused on immunotherapy in the region. The high prevalence of cancer and regulatory support from the FDA further aid the market growth. Moreover, the rise in the number of clinical trials in immunotherapy and substantial research and development investments to advance cancer care are poised to fuel the market expansion in the region.

Key Offerings of the Report

• The Expert Market Research report gives an overview of the market for immunotherapy for oncology for the time span of (2019-2025) and (2026-2035).
• The report also offers historical (2019-2025) and forecast (2026-2035) market information for the type, indication, route of administration, end user, and region of the market.
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which is constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790